View all cases
UPC CFI 124/2024
Mar 19, 2024·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT
- Case details
- StatusCase ClosedActionProvisional measuresCategoryProvisional Measures
- Parties
- Division
- Hamburg LD
- Technology
- Organic Chemistry
- Language
- English
- First decided
- Jun 26, 2024
Decisions
- 2024-06-26PI deniedPreliminary injunctionApplication for provisional measures
The Hamburg Local Division dismissed Alexion Pharmaceuticals' application for a preliminary injunction against multiple Amgen entities based on EP 3 167 888, holding that while infringement could be established the court lacked sufficient certainty of patent validity given the EPO's repeated rejection of sequence correction attempts for SEQ ID NO:4.
Legal issues:preliminary injunction standard Art. 62(2) UPCAvalidity certainty requirement Art. 62(4) UPCASEQ ID NO:4 disclosure and correction history
Documents
| Document title | Date | Public |
|---|---|---|
| action.phaseChange.caseClose | 2025-12-05 | Not public |
| action.issueOrder.order | 2025-12-05 | Not public |
| Order | 2025-12-05 | Not public |
| Cover sheet | 2025-12-03 | Not public |
| Other document Defendant | 2025-12-03 | Not public |
| Other document Defendant | 2025-12-03 | Not public |
| Receipt | 2025-12-03 | Not public |
| action.issueOrder.order | 2025-12-02 | Not public |
| Order | 2025-12-02 | Not public |
| Cover sheet | 2025-11-26 | Not public |
| Other document Claimant | 2025-11-26 | Not public |
| Receipt | 2025-11-26 | Not public |
| Comments | 2025-09-18 | Not public |
| Outcome of the Order | 2025-09-10 | Not public |
| deadline extension | 2025-09-10 | Public |
| Receipt | 2025-09-10 | Not public |
| Receipt | 2025-09-10 | Not public |
| 262.2 Application | 2025-09-09 | Not public |
| Deadline extension request | 2025-09-09 | Not public |
| Deadline extension request | 2025-09-09 | Not public |
| anonymisierte Version | 2025-09-04 | Not public |
| anonymisierte Version | 2025-09-04 | Not public |
| Anhoerung | 2025-08-26 | Not public |
| Template-Order | 2025-08-26 | Not public |
| Outcome of the Order | 2025-08-25 | Not public |
| Order with grounds | 2025-08-25 | Public |
| Receipt | 2025-08-20 | Not public |
| 20250820_Application_for_rectification_Amgen_EN signiert | 2025-08-20 | Not public |
| Receipt | 2025-08-20 | Not public |
| Receipt | 2025-08-20 | Not public |
| Receipt | 2025-08-20 | Not public |
| Receipt | 2025-08-20 | Not public |
| Receipt | 2025-08-20 | Not public |
| Receipt | 2025-08-20 | Not public |
| Receipt | 2025-08-20 | Not public |
| Application_262_2_RoP_Costs_Rehearing_Amgen_33361_2025 signed | 2025-08-19 | Not public |
| Application_262_2_RoP_Costs_Appeal_Proceedings_Amgen_3053_2025 signed | 2025-08-19 | Not public |
| Application_262_2_RoP_Costs_First_Instance_Amgen_43687_2024 signed | 2025-08-19 | Not public |
| 2025-07-21 Rehearing - Application for cost decision - Amgen - signed - confidential | 2025-08-19 | Not public |
| Request_9_1_RoP_Costs_Rehearing_Amgen_33361_2025_35088_2025 signed | 2025-08-19 | Not public |
| 2025-07-21 Rehearing - Application for cost decision - Amgen - signed - confidential | 2025-08-19 | Not public |
| 2025-01-20 Second Instance - Application for cost decision - Amgen - signed - confidential | 2025-08-19 | Not public |
| 2025-01-20 Second Instance - Application for cost decision - Amgen - signed - confidential | 2025-08-19 | Not public |
| Request_9_1_RoP_Costs_Appeal_Proceedings_Amgen_3053_2025_35087_2025 signed | 2025-08-19 | Not public |
| 2024-07-26 First Instance - Application for cost decision - Amgen - signed - confidential | 2025-08-19 | Not public |
| 2024-07-26 First Instance - Application for cost decision - Amgen - signed - confidential | 2025-08-19 | Not public |
| Request_9_1_RoP_Costs_First_Instance_Amgen_43687_2025_35086_2025 signed | 2025-08-19 | Not public |
| 2025-07-14 First Instance - Reply of Amgen - 43687_2024 - signed - confidential | 2025-08-19 | Not public |
| 2025-07-14 First Instance - Reply of Amgen - 43687_2024 - signed - confidential | 2025-08-19 | Not public |
| Comments on application for rehearing costs | 2025-08-19 | Not public |
| 262a | 2025-08-05 | Not public |
| 262a | 2025-08-05 | Not public |
| 262a | 2025-08-05 | Not public |
| 262A | 2025-08-05 | Not public |
| Anhoerung | 2025-08-05 | Not public |
| Outcome of the Order | 2025-08-05 | Not public |
| Order with grounds | 2025-08-05 | Not public |
| Order with grounds | 2025-08-05 | Public |
| Order with grounds | 2025-08-05 | Public |
| Order with grounds | 2025-08-05 | Not public |
| Comments | 2025-08-04 | Not public |
| Anhoerung | 2025-07-28 | Not public |
| Receipt | 2025-07-22 | Not public |
| Receipt | 2025-07-22 | Not public |
| Confidentiality_Request_re_Application_cost_decision_rehearing_EN | 2025-07-21 | Not public |
| Confidentiality_Request_re_Application_cost_decision_rehearing_EN | 2025-07-21 | Not public |
| Application_cost_decision_rehearing_Confidential_EN | 2025-07-21 | Not public |
| Application_cost_decision_rehearing_Confidential_EN | 2025-07-21 | Not public |
| Outcome of the Order | 2024-09-30 | Not public |
| Confirmation of appointment – oral hearing recording | 2024-09-30 | Public |
| Receipt | 2024-09-26 | Not public |
| Request to the Registrar for the recording of the oral hearing to be made available | 2024-09-25 | Not public |
| Order with grounds (ORD_38132_2024) | 2024-07-17 | Not public |
| Measures_DecisionOutcome_Notification.pdf | 2024-06-26 | Not public |
| procedural order | 2024-06-26 | Public |
| Recording | 2024-06-26 | Not public |
| Recording | 2024-06-26 | Not public |
| summons | 2024-06-25 | Not public |
| closing written proceedings | 2024-06-25 | Public |
| Closing workflow | 2024-06-18 | Public |
| Comments | 2024-06-14 | Not public |
| Exhibit FBD 38a | 2024-06-14 | Not public |
| Exhibit_BP20 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP23 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP22 | 2024-06-14 | Not public |
| Exhibit_BP24 | 2024-06-14 | Not public |
| Exhibit_BP18 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP27 | 2024-06-14 | Not public |
| Exhibit_BP28 | 2024-06-14 | Not public |
| Exhibit_BP25 | 2024-06-14 | Not public |
| Exhibit_BP17 | 2024-06-14 | Not public |
| Exhibit_BP19 | 2024-06-14 | Not public |
| Exhibit_BP21 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP26 | 2024-06-14 | Not public |
| Exhibit_BP24 | 2024-06-14 | Not public |
| Exhibit_BP27 | 2024-06-14 | Not public |
| Exhibit_BP20 | 2024-06-14 | Not public |
| Exhibit_BP18 | 2024-06-14 | Not public |
| Exhibit_BP23 | 2024-06-14 | Not public |
| Exhibit_BP19 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP17 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP26 | 2024-06-14 | Not public |
| Exhibit_BP25 | 2024-06-14 | Not public |
| Exhibit_BP21 | 2024-06-14 | Not public |
| Exhibit_BP28 | 2024-06-14 | Not public |
| Exhibit_BP22 | 2024-06-14 | Not public |
| Exhibit_BP18 | 2024-06-14 | Not public |
| Exhibit_BP22 | 2024-06-14 | Not public |
| Exhibit_BP25 | 2024-06-14 | Not public |
| Exhibit_BP17 | 2024-06-14 | Not public |
| Exhibit_BP21 | 2024-06-14 | Not public |
| Exhibit_BP19 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP28 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP23 | 2024-06-14 | Not public |
| Exhibit_BP20 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP26 | 2024-06-14 | Not public |
| Exhibit_BP24 | 2024-06-14 | Not public |
| Exhibit_BP27 | 2024-06-14 | Not public |
| Exhibit_BP21 | 2024-06-14 | Not public |
| Exhibit_BP27 | 2024-06-14 | Not public |
| Exhibit_BP20 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP23 | 2024-06-14 | Not public |
| Exhibit_BP28 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP26 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP24 | 2024-06-14 | Not public |
| Exhibit_BP17 | 2024-06-14 | Not public |
| Exhibit_BP22 | 2024-06-14 | Not public |
| Exhibit_BP25 | 2024-06-14 | Not public |
| Exhibit_BP18 | 2024-06-14 | Not public |
| Exhibit_BP19 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP21 | 2024-06-14 | Not public |
| Exhibit_BP20 | 2024-06-14 | Not public |
| Exhibit_BP26 | 2024-06-14 | Not public |
| Exhibit_BP27 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP24 | 2024-06-14 | Not public |
| Exhibit_BP19 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP17 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP28 | 2024-06-14 | Not public |
| Exhibit_BP25 | 2024-06-14 | Not public |
| Exhibit_BP18 | 2024-06-14 | Not public |
| Exhibit_BP22 | 2024-06-14 | Not public |
| Exhibit_BP23 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP18 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP24 | 2024-06-14 | Not public |
| Exhibit_BP21 | 2024-06-14 | Not public |
| Exhibit_BP25 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP28 | 2024-06-14 | Not public |
| Exhibit_BP23 | 2024-06-14 | Not public |
| Exhibit_BP17 | 2024-06-14 | Not public |
| Exhibit_BP27 | 2024-06-14 | Not public |
| Exhibit_BP26 | 2024-06-14 | Not public |
| Exhibit_BP19 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP22 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP20 | 2024-06-14 | Not public |
| Exhibit_BP26 | 2024-06-14 | Not public |
| Exhibit_BP21 | 2024-06-14 | Not public |
| Exhibit_BP19 | 2024-06-14 | Not public |
| Exhibit_BP18 | 2024-06-14 | Not public |
| Exhibit_BP24 | 2024-06-14 | Not public |
| Exhibit_BP27 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP25 | 2024-06-14 | Not public |
| Exhibit_BP28 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP23 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP22 | 2024-06-14 | Not public |
| Exhibit_BP17 | 2024-06-14 | Not public |
| Exhibit_BP20 | 2024-06-14 | Not public |
| Exhibit_BP26 | 2024-06-14 | Not public |
| Exhibit_BP24 | 2024-06-14 | Not public |
| Exhibit_BP19 | 2024-06-14 | Not public |
| Exhibit_BP18 | 2024-06-14 | Not public |
| Exhibit_BP27 | 2024-06-14 | Not public |
| Exhibit_BP23 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP25 | 2024-06-14 | Not public |
| Exhibit_BP28 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP17 | 2024-06-14 | Not public |
| Exhibit_BP20 | 2024-06-14 | Not public |
| Exhibit_BP21 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP22 | 2024-06-14 | Not public |
| Exhibit_BP25 | 2024-06-14 | Not public |
| Exhibit_BP22 | 2024-06-14 | Not public |
| Exhibit_BP21 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP26 | 2024-06-14 | Not public |
| Exhibit_BP17 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP23 | 2024-06-14 | Not public |
| Exhibit_BP24 | 2024-06-14 | Not public |
| Exhibit_BP29 - confidential | 2024-06-14 | Not public |
| Exhibit_BP18 | 2024-06-14 | Not public |
| Exhibit_BP27 | 2024-06-14 | Not public |
| Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed | 2024-06-14 | Not public |
| Exhibit_BP19 | 2024-06-14 | Not public |
| Exhibit_BP28 | 2024-06-14 | Not public |
| Exhibit_BP20 | 2024-06-14 | Not public |
| Vorlage Skerra | 2024-06-14 | Not public |
| Outcome of the Order | 2024-05-28 | Not public |
| Deadline amgen | 2024-05-28 | Public |
| Receipt | 2024-05-28 | Not public |
| Application/Submission | 2024-05-27 | Not public |
| Outcome of the Order | 2024-05-24 | Not public |
| Closing workflow | 2024-05-24 | Public |
| Duplik Defendant | 2024-05-24 | Not public |
| Receipt | 2024-05-24 | Not public |
| R 262 Application | 2024-05-24 | Not public |
| Exhibit FBD 56 | 2024-05-24 | Not public |
| Exhibit FBD 63 | 2024-05-24 | Not public |
| Exhibit FBD 61 | 2024-05-24 | Not public |
| Exhibit FBD 52 | 2024-05-24 | Not public |
| Exhibit FBD 54 | 2024-05-24 | Not public |
| Part I of the Reply | 2024-05-24 | Not public |
| Exhibit FBD 43 | 2024-05-24 | Not public |
| Exhibit FBD 47 | 2024-05-24 | Not public |
| Exhibit FBD 51 | 2024-05-24 | Not public |
| Exhibit FBD 53 | 2024-05-24 | Not public |
| Part II of the Reply | 2024-05-24 | Not public |
| Exhibit FBD 37 | 2024-05-24 | Not public |
| Exhibit FBD 55 | 2024-05-24 | Not public |
| Exhibit FBD 57 | 2024-05-24 | Not public |
| Exhibit FBD 40 | 2024-05-24 | Not public |
| Exhibit FBD 49 | 2024-05-24 | Not public |
| Exhibit FBD-A 2 | 2024-05-24 | Not public |
| Part II of the Reply | 2024-05-24 | Not public |
| Exhibit FBD 38 | 2024-05-24 | Not public |
| Exhibit FBD 66 | 2024-05-24 | Not public |
| Exhibit FBD 64 | 2024-05-24 | Not public |
| Exhibit FBD 41 | 2024-05-24 | Not public |
| Exhibit FBD 42 | 2024-05-24 | Not public |
| Exhibit FBD 62 | 2024-05-24 | Not public |
| Exhibit FBD 46 | 2024-05-24 | Not public |
| Exhibit FBD 65 | 2024-05-24 | Not public |
| Exhibit FBD 60 | 2024-05-24 | Not public |
| Exhibit FBD 35 | 2024-05-24 | Not public |
| Exhibit FBD 59 | 2024-05-24 | Not public |
| Exhibit FBD 45 | 2024-05-24 | Not public |
| Exhibit FBD 67 | 2024-05-24 | Not public |
| Exhibit FBD 48 | 2024-05-24 | Not public |
| Exhibit FBD 50 | 2024-05-24 | Not public |
| Exhibit FBD-A 1 | 2024-05-24 | Not public |
| Exhibit FBD 36 | 2024-05-24 | Not public |
| Exhibit FBD 58 | 2024-05-24 | Not public |
| Exhibit FBD 44 | 2024-05-24 | Not public |
| Exhibit FBD 66 | 2024-05-24 | Not public |
| Exhibit FBD 39 | 2024-05-24 | Not public |
| Outcome of the Order | 2024-05-16 | Not public |
| Frist | 2024-05-16 | Public |
| Receipt | 2024-05-16 | Not public |
| Anlage FBD FV 1 | 2024-05-16 | Not public |
| Rule 9.3 Extension request | 2024-05-16 | Not public |
| Anlage FBD FV 2 | 2024-05-16 | Not public |
| Outcome of the Order | 2024-05-07 | Not public |
| Frist applicant | 2024-05-07 | Public |
| summon to oral hearing | 2024-05-03 | Not public |
| Receipt | 2024-05-02 | Not public |
| Exhibit_BP10_Amgen_Related_proceedings_confidential_en | 2024-04-30 | Not public |
| Exhibit_BP09h_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP14_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP10e_Amgen_confidential_nl | 2024-04-30 | Not public |
| Exhibit_BP09f_Amgen_en | 2024-04-30 | Not public |
| Objection_Amgen_dd_April_30_2024_Confidential_en_signed | 2024-04-30 | Not public |
| Exhibit_BP09b_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP12_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP15_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP09c_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP00_Amgen_en_signed | 2024-04-30 | Not public |
| Exhibit_BP04_Amgen_Confidential_en | 2024-04-30 | Not public |
| Exhibit_BP09d_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP09m_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP09i_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP07_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP08_Amgen_Table_Grant_procedures_en | 2024-04-30 | Not public |
| Exhibit_BP10e_Amgen_confidential_nl | 2024-04-30 | Not public |
| Exhibit_BP02_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP10a_Amgen_confidential_de | 2024-04-30 | Not public |
| Exhibit_BP10_Amgen_Related_proceedings_confidential_en | 2024-04-30 | Not public |
| Exhibit_BP09n_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP10b_Amgen_confidential_en | 2024-04-30 | Not public |
| Exhibit_BP10d_Amgen_confidential_en | 2024-04-30 | Not public |
| Exhibit_BP10c_Amgen_confidential_en | 2024-04-30 | Not public |
| Exhibit_BP10c_Amgen_confidential_en | 2024-04-30 | Not public |
| Exhibit_BP09l_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP09a_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP03_Amgen_Technical_background_en | 2024-04-30 | Not public |
| Exhibit_BP01_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP10d_Amgen_confidential_en | 2024-04-30 | Not public |
| Exhibit_BP13_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP06_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP09p_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP09j_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP05_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP09g_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP11_Amgen_file_wrapper_estoppel_en | 2024-04-30 | Not public |
| Exhibit_BP09o_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP04_Amgen_Confidential_en | 2024-04-30 | Not public |
| Exhibit_BP09e_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP16_Amgen_en | 2024-04-30 | Not public |
| Exhibit_BP09_Amgen_Grant_history_en | 2024-04-30 | Not public |
| Objection_Amgen_dd_April_30_2024_Confidential_en_signed | 2024-04-30 | Not public |
| Exhibit_BP10a_Amgen_confidential_de | 2024-04-30 | Not public |
| Exhibit_BP10b_Amgen_confidential_en | 2024-04-30 | Not public |
| Exhibit_BP09k_Amgen_en | 2024-04-30 | Not public |
| Panel-Appointment | 2024-04-17 | Not public |
| Procedural Order | 2024-04-14 | Not public |
| Template-Order | 2024-04-14 | Not public |
| Receipt | 2024-04-09 | Not public |
| Antrag/Schriftsatz | 2024-04-09 | Not public |
| Notification Of Service | 2024-04-09 | Not public |
| Mail Service Sweden | 2024-04-09 | Not public |
| Acknowledgement of access to case | 2024-04-09 | Not public |
| Acknowledgement of access to case | 2024-04-02 | Not public |
| Acknowledgement of access to case | 2024-04-02 | Not public |
| Acknowledgement of access to case | 2024-04-02 | Not public |
| Acknowledgement of access to case | 2024-04-02 | Not public |
| Acknowledgement of access to case | 2024-04-02 | Not public |
| Acknowledgement of access to case | 2024-04-02 | Not public |
| Acknowledgement of access to case | 2024-04-02 | Not public |
| Acknowledgement of access to case | 2024-04-02 | Not public |
| Notification Of Service | 2024-03-28 | Not public |
| Service Italy | 2024-03-28 | Not public |
| Service Italien | 2024-03-28 | Not public |
| Notification Of Service | 2024-03-28 | Not public |
| Service French | 2024-03-28 | Not public |
| Service Frankreich | 2024-03-28 | Not public |
| Notification Of Service | 2024-03-27 | Not public |
| Service Portugal | 2024-03-27 | Not public |
| Notification Of Service | 2024-03-27 | Not public |
| Service Belgium | 2024-03-27 | Not public |
| Notification Of Service | 2024-03-27 | Not public |
| Service Munich | 2024-03-27 | Not public |
| Notification Of Service | 2024-03-26 | Not public |
| Service Ireland | 2024-03-26 | Not public |
| Panel-Appointment | 2024-03-26 | Not public |
| Notification Of Service | 2024-03-26 | Not public |
| Service Slovenia | 2024-03-26 | Not public |
| Notification Of Service | 2024-03-26 | Not public |
| Service Austria | 2024-03-26 | Not public |
| Invitation to lodge | 2024-03-20 | Public |
| Letter for Service | 2024-03-20 | Not public |
| Letter for Service | 2024-03-20 | Not public |
| Letter for Service | 2024-03-20 | Not public |
| Letter for Service | 2024-03-20 | Not public |
| Letter for Service | 2024-03-20 | Not public |
| Letter for Service | 2024-03-20 | Not public |
| Letter for Service | 2024-03-20 | Not public |
| Letter for Service | 2024-03-20 | Not public |
| Letter for Service | 2024-03-20 | Not public |
| Receipt | 2024-03-20 | Not public |
| Application to request confidentiality from the public | 2024-03-19 | Not public |
| Panel-Appointment | 2024-03-19 | Not public |
| Application-For-Measures-Receipt | 2024-03-19 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-03-19 | Not public |
| Application-For-Measures-Acknowledgement | 2024-03-19 | Not public |
| Exhibit FBD 17a | 2024-03-19 | Not public |
| Exhibit FBD 4 | 2024-03-19 | Not public |
| Confidential Exhibit FBD 2 | 2024-03-19 | Not public |
| Application for Provisional Measures | 2024-03-19 | Not public |
| Exhibit FBD 18a | 2024-03-19 | Not public |
| Exhibit FBD 15 | 2024-03-19 | Not public |
| Exhibit FBD 27 | 2024-03-19 | Not public |
| Exhibit FBD 16 | 2024-03-19 | Not public |
| Confidential Exhibit FBD 2 | 2024-03-19 | Not public |
| Set of Exhibits FBD 5b | 2024-03-19 | Not public |
| Set of Exhibits FBD 5a | 2024-03-19 | Not public |
| Exhibit FBD 28 | 2024-03-19 | Not public |
| Exhibit FBD 18 | 2024-03-19 | Not public |
| Exhibit FBD 17b | 2024-03-19 | Not public |
| Exhibit FBD 3 | 2024-03-19 | Not public |
| Exhibit FBD 29 | 2024-03-19 | Not public |
| Exhibit FBD 33a | 2024-03-19 | Not public |
| Exhibit FBD 26 | 2024-03-19 | Not public |
| Exhibit FBD 11 | 2024-03-19 | Not public |
| Exhibit FBD 7 | 2024-03-19 | Not public |
| Exhibit FBD 12 | 2024-03-19 | Not public |
| Exhibit FBD 9 | 2024-03-19 | Not public |
| Exhibit FBD 6 | 2024-03-19 | Not public |
| Exhibit FBD 17c | 2024-03-19 | Not public |
| Exhibit FBD 25 | 2024-03-19 | Not public |
| Exhibit FBD 21 | 2024-03-19 | Not public |
| Exhibit FBD 10 | 2024-03-19 | Not public |
| Exhibit FBD 1 | 2024-03-19 | Not public |
| Exhibit FBD 8 | 2024-03-19 | Not public |
| Exhibit FBD 23 | 2024-03-19 | Not public |
| Application for Provisional Measures | 2024-03-19 | Not public |
| Exhibit FBD 14 | 2024-03-19 | Not public |
| Exhibit FBD 31 | 2024-03-19 | Not public |
| Exhibit FBD 32 | 2024-03-19 | Not public |
| Exhibit FBD 34 | 2024-03-19 | Not public |
| Exhibit FBD 0 | 2024-03-19 | Not public |
| Exhibit FBD 24 | 2024-03-19 | Not public |
| Exhibit FBD 30 | 2024-03-19 | Not public |
| Exhibit FBD 20 | 2024-03-19 | Not public |
| Exhibit FBD 22 | 2024-03-19 | Not public |
| Exhibit FBD 19 | 2024-03-19 | Not public |
| Exhibit FBD 33 | 2024-03-19 | Not public |
| Exhibit FBD 13 | 2024-03-19 | Not public |
| Exhibit FBD 32a | 2024-03-19 | Not public |
Plain-English summary
Alexion Pharmaceuticals applied for a preliminary injunction at the Hamburg Local Division against nine Amgen entities across multiple European countries regarding EP 3 167 888 B1 (eculizumab/paroxysmal nocturnal haemoglobinuria). Identical reasoning to UPC_CFI_123/2024: the court found infringement could be established but denied the measure because the TBA's consistent rejection of SEQ ID NO:4 correction attempts created insufficient certainty of patent validity; value of dispute was EUR 100,000,000.
Accepted arguments
What the court agreed with — by party.
Sufficient certainty of patent validity is required before granting provisional measures, assessed in light of likely EPO outcome
RespondentLegal basis: Art. 62(4) UPCA; R. 211.2 RoPNote: Same legal reasoning as UPC_CFI_123/2024: the Hamburg court declined the PI because TBA history created serious doubt about EP 3 167 888 B1's validity.
Rejected arguments
What the court did not agree with — and why.
Preliminary injunction against Amgen entities based on EP 3 167 888 B1
ClaimantLegal basis: Art. 62(4) UPCA; R. 211.2 RoPReason: Although infringement could be established, the court lacked sufficient certainty of patent validity given the TBA's consistent rejection of all attempts to correct SEQ ID NO:4 and claim sets directed to eculizumab across the EP 888 patent family.
Key legal principles
Doctrines and rules cited in the reasoning.
Provisional measures require sufficient certainty of patent validity, not merely the court's own viewCourt must consider the likelihood of EPO opposition/TBA outcome when assessing validityPatent claims interpreted from the skilled person's perspective, considering purposeValidity doubt from consistent adverse TBA history defeats a PI application
Browse other cases on this principle.
Claim construction notes
Identical to UPC_CFI_123/2024: the court construed EP 3 167 888 claims but found it could not be sufficiently certain of validity given the TBA's repeated holdings that SEQ ID NO:4 includes the signal peptide sequence and its refusal to allow correction.